patisiran

Biotech stocks had a fairly decent run up in July after a nearly flat performance in June. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is up about 5 percent. As the earnings season kicks into high gear and amid several other catalysts, August is likely to be an action-packed...

Arbutus Biopharma Corp (NASDAQ: ABUS) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally.   The Analyst B. Riley FBR's Madhu Kumar downgraded Arbutus Biopharma from Buy to Neutral with an unchanged $...

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is taking on a broad list of indications with RNAi therapeutics, from bleeding disorders to hypercholesterolemia to amyloidosis. “We’re really building a company that can emerge as a top five biotech company over the next five or so years,...

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) surged higher by more than 20 percent early Wednesday morning after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through...

Morgan Stanley in a research note released Monday noted that the Data Monitoring Committee has recommended Alnylam Pharmaceuticals, Inc.(NASDAQ: ALNY) continue with the trail without modification, following examination of safety data from the Phase III hATTR-PN trial. That said, the firm believes...